Head & Neck Cancer Patient Enrolled in Individualized Immunotherapy Study

France-based Transgene announced that the first United Kingdom (UK) patient has been enrolled in a Phase I clinical trial of TG4050, an innovative individualized cancer immunotherapy, currently being evaluated in HPV-negative head and neck cancer patients.

TG4050 is a therapeutic vaccine based on cutting-edge Artificial Intelligence (AI) capabilities to customize the treatment for each patient.

The innovative approach behind TG4050 combines Transgene’s expertise in virus-based immunotherapies, NEC’s longstanding AI technologies, and the commitment of prestigious cancer care centers in the UK, the European Union, and the USA.

The trial is led by the coordinating investigator Professor Christian Ottensmeier, M.D., Ph.D., Consultant Medical Oncologist at The Clatterbridge Cancer Centre and Professor of Immuno-Oncology at the University of Liverpool.

Professor Ottensmeier commented in a press statement issued on June 28, 2021, “We are pioneering the personalized cancer vaccine field. If successful, this technique could be a potentially game-changing development in the treatment of advanced head and neck cancers. We have spent the last 15 years working on the science behind this immunotherapy so it is very gratifying to be beginning clinical trials with the first patient being enrolled in the UK."

"Head and neck cancers are particularly complex to treat if they spread and cannot then be completely removed surgically. Personalized cancer vaccines are an extremely exciting development and, if successful, the same technique could also be applied to treat other forms of cancer.”

Located in Strasbourg, France, Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.